Psychological morbidity associated with ovarian cancer screening: results from more than 23 000 women in the randomised trial of ovarian cancer screening (UKCTOCS)

被引:37
|
作者
Barrett, J. [1 ]
Jenkins, V. [2 ]
Farewell, V. [3 ]
Menon, U. [4 ]
Jacobs, I. [5 ]
Kilkerr, J. [2 ]
Ryan, A. [4 ]
Langridge, C. [2 ]
Fallowfield, L. [2 ]
机构
[1] Univ Cambridge, Dept Publ Hlth & Primary Care, Cardiovasc Epidemiol Unit, Cambridge, England
[2] Univ Sussex, SHORE C, Brighton BN1 9RX, E Sussex, England
[3] Inst Publ Hlth, Med Res Council Biostat Unit, Cambridge, England
[4] UCL, EGA Inst Womens Hlth, London, England
[5] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Anxiety; ovarian cancer; population screening; programme; psychological morbidity; QUALITY-OF-LIFE; METAANALYSIS; ADHERENCE; RISK;
D O I
10.1111/1471-0528.12870
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To examine the psychological sequelae associated with abnormal screening in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Design Prospective, longitudinal randomised control trial. Setting Sixteen UKCTOCS centres. Sample Women aged 50-70 years randomised to annual multimodal screening, ultrasound screening or control groups. Methods Two groups were followed for 7 years: (1) a random sample (n = 1339), taken from all three study groups; and (2) an events sample (n = 22 035) of women with abnormal screens resulting in the need for repeat testing of either low or higher level intensity. Main outcome measures Patient-reported measures of anxiety (scores ranging from 20 to 80) and psychological morbidity. Results In the random sample the mean difference between anxiety scores after a repeat screening and those following an annual screening was 0.4 (95% CI -0.46, 1.27), and in the events sample it was 0.37 (95% CI 0.23, 0.51). The risk of psychological morbidity was only increased in the event sample for women requiring higher level repeat screening (OR 1.28; 95% CI 1.18, 1.39). The risk of psychological morbidity in women with ovarian cancer was higher at both 6 weeks (OR 16.2; 95% CI 9.19, 28.54) and 6 months (OR 3.32; 95% CI 1.91, 5.77) following surgery. Conclusions Screening does not appear to raise anxiety but psychological morbidity is elevated by more intense repeat testing following abnormal annual screens, and in women after surgical treatment for ovarian cancer.
引用
收藏
页码:1071 / 1079
页数:9
相关论文
共 50 条
  • [1] Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
    Jacobs, Ian J.
    Menon, Usha
    Ryan, Andy
    Gentry-Maharaj, Aleksandra
    Burnell, Matthew
    Kalsi, Jatinderpal K.
    Amso, Nazar N.
    Apostolidou, Sophia
    Benjamin, Elizabeth
    Cruickshank, Derek
    Crump, Danielle N.
    Davies, Susan K.
    Dawnay, Anne
    Dobbs, Stephen
    Fletcher, Gwendolen
    Ford, Jeremy
    Godfrey, Keith
    Gunu, Richard
    Habib, Mariam
    Hallett, Rachel
    Herod, Jonathan
    Jenkins, Howard
    Karpinskyj, Chloe
    Leeson, Simon
    Lewis, Sara J.
    Liston, William R.
    Lopes, Alberto
    Mould, Tim
    Murdoch, John
    Oram, David
    Rabideau, Dustin J.
    Reynolds, Karina
    Scott, Ian
    Seif, Mourad W.
    Sharma, Aarti
    Singh, Naveena
    Taylor, Julie
    Warburton, Fiona
    Widschwendter, Martin
    Williamson, Karin
    Woolas, Robert
    Fallowfield, Lesley
    McGuire, Alistair J.
    Campbell, Stuart
    Parmar, Mahesh
    Skates, Steven J.
    LANCET, 2016, 387 (10022): : 945 - 956
  • [2] Ovarian cancer screening: UKCTOCS trial
    Hoskins, Paul
    Gotlieb, Walter
    LANCET, 2016, 387 (10038): : 2602 - 2603
  • [3] Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial
    Jacobs, Ian J.
    Menon, Usha
    Ryan, Andy
    Gentry-Maharaj, Aleksandra
    Burnell, Matthew
    Kalsi, Jatinderpal K.
    McGuire, Alistair J.
    Farmer, Mahesh
    Skates, Steven J.
    CANCER RESEARCH, 2016, 76
  • [4] The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    Usha Menon
    Alistair J McGuire
    Maria Raikou
    Andy Ryan
    Susan K Davies
    Matthew Burnell
    Aleksandra Gentry-Maharaj
    Jatinderpal K Kalsi
    Naveena Singh
    Nazar N Amso
    Derek Cruickshank
    Stephen Dobbs
    Keith Godfrey
    Jonathan Herod
    Simon Leeson
    Tim Mould
    John Murdoch
    David Oram
    Ian Scott
    Mourad W Seif
    Karin Williamson
    Robert Woolas
    Lesley Fallowfield
    Stuart Campbell
    Steven J Skates
    Mahesh Parmar
    Ian J Jacobs
    British Journal of Cancer, 2017, 117 : 619 - 627
  • [5] The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    Menon, Usha
    McGuire, Alistair J.
    Raikou, Maria
    Ryan, Andy
    Davies, Susan K.
    Burnell, Matthew
    Gentry-Maharaj, Aleksandra
    Kalsi, Jatinderpal K.
    Singh, Naveena
    Amso, Nazar N.
    Cruickshank, Derek
    Dobbs, Stephen
    Godfrey, Keith
    Herod, Jonathan
    Leeson, Simon
    Mould, Tim
    Murdoch, John
    Oram, David
    Scott, Ian
    Seif, Mourad W.
    Williamson, Karin
    Woolas, Robert
    Fallowfield, Lesley
    Campbell, Stuart
    Skates, Steven J.
    Parmar, Mahesh
    Jacobs, Ian J.
    BRITISH JOURNAL OF CANCER, 2017, 117 (05) : 619 - 627
  • [6] Ovarian cancer screening: UKCTOCS trial Reply
    Jacobs, Ian J.
    Parmar, Mahesh
    Skates, Steven J.
    Menon, Usha
    LANCET, 2016, 387 (10038): : 2603 - 2604
  • [7] OVERDIAGNOSIS OF BORDERLINE OVARIAN CANCER IN OVARIAN CANCER SCREENING: THE UK COLLABORATIVE TRIAL OF OVARIAN CANCER SCREENING (UKCTOCS) EXPERIENCE
    Gentry-Maharaj, A.
    Karpinskyj, C.
    Taylor, H.
    Ryan, A.
    Singh, N.
    Benjamin, E.
    Widschwendter, M.
    Burnell, M.
    Davies, S.
    Kalsi, J.
    Skates, S.
    Campbell, S.
    Parmar, M.
    Jacobs, I.
    Menon, U.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 22 - 23
  • [8] Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomized Controlled Trial
    Jacobs, Ian J.
    Menon, Usha
    Ryan, Andy
    Gentry-Maharaj, Aleksandra
    Burnell, Matthew
    Kalsi, Jatinderpal K.
    Amso, Nazar N.
    Apostolidou, Sophia
    Benjamin, Elizabeth
    Cruickshank, Derek
    Crump, Danielle N.
    Davies, Susan K.
    Dawnay, Anne
    Dobbs, Stephen
    Fletcher, Gwendolen
    Ford, Jeremy
    Godfrey, Keith
    Gunu, Richard
    Habib, Mariam
    Hallett, Rachel
    Herod, Jonathan
    Jenkins, Howard
    Karpinskyj, Chloe
    Leeson, Simon
    Lewis, Sara J.
    Liston, William R.
    Lopes, Alberto
    Mould, Tim
    Murdoch, John
    Oram, David
    Rabideau, Dustin J.
    Reynolds, Karina
    Scott, Ian
    Seif, Mourad W.
    Sharma, Aarti
    Singh, Naveena
    Taylor, Julie
    Warburton, Fiona
    Widschwendter, Martin
    Williamson, Karin
    Woolas, Robert
    Fallowfield, Lesley
    McGuire, Alistair J.
    Campbell, Stuart
    Parmar, Mahesh
    Skates, Steven J.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2016, 71 (06) : 346 - 348
  • [9] UKCTOCS and the evaluation of screening for ovarian cancer
    不详
    LANCET, 2016, 387 (10022): : 918 - 918
  • [10] SCREENING FOR OVARIAN CANCER AND THE CHALLENGES AHEAD: RESULTS FROM THE MULTICENTRE UKCTOCS STUDY
    Amso, Nazar N.
    ANTICANCER RESEARCH, 2015, 35 (07) : 4300 - 4300